berotralstat
Commercial- Indications
- Hereditary angioedema
Company intelligence / Profile preview
Pint Pharma
Vienna, Vienna, Austriapint-pharma.com ↗
- Ownership
- Private
- Employees
- ~233
- Development stage
- Commercial
01
Overview
Recently received approval for ORLADEYO® (berotralstat) in Peru, the first oral therapy indicated to prevent hereditary angioedema (HAE) attacks in adults and children 12 years and older[3]
- Therapeutic areas
- ImmunologyOncologyRare Diseases
- Modalities
- Biotechnologies
- Industry
- Biotech
02
Drug pipeline
2 assets1 more asset in the full pipeline.
Request access →Beyond the preview
Go deeper on Pint Pharma.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Pint Pharma.